Company
AexeRNA Therapeutics
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
was co-founded by Linden Lake to develop novel mRNA therapeutics and vaccines, leveraging a proprietary high-potency next generation mRNA lipid nanoparticle delivery platform technology. The technology was developed by the late Prof. Mike Buschmann at George Mason University's Volgenau School of Engineering and National Center for Biodefense and Infectious Diseases and Prof. Drew Weisman at the University of Pennsylvania.
Loading relationship preview